Bictegravir/Emtricitabine/Tenofovir alafenamide Approved to Treat Pediatric Patients With HIV
The pediatric approval was based on data from an open label, single arm trial that evaluated the efficacy, safety, and pharmacokinetics of Biktarvy in virologically suppressed children (6 to <12 years old; n=50) and adolescents (12 to <18 years old; n=50).
